Blood and Hematopoiesis Overview
Hematopoiesis and Blood Cell Production (Video Transcript)
Hematopoiesis (hemopoiesis) = production of red blood cells (RBCs), white blood cells (WBCs), and platelets. In this lecture, focus is on RBCs and platelets; the production site emphasized is red bone marrow.
Location: red bone marrow labeled in the diagram (labeled as a red tube in the lecture).
Stem cells in red bone marrow give rise to all blood lineages; daughter cells differentiate into specific lineages (→ RBCs, WBCs, platelets).
Two primary differentiation pathways shown:
Left path: RBC production from the hemocytoblast → pro erythroblast → red blood cell.
Right path: Platelet production from the hemocytoblast → megakaryoblast → megakaryocyte → platelets.
Important note: RBCs and platelets are produced via these two separate but related pathways.
Erythropoiesis (RBC production) details
The first step: a hemocytoblast divides and differentiates into a proerythroblast (daughter of the hemocytoblast).
From proerythroblast to mature RBC involves about 25–30 steps; the lecture emphasizes the end product (RBC) rather than detailing all steps.
A hormone is required for RBC production: erythropoietin (EPO).
EPO is produced by the kidneys (two kidneys).
EPO is released into the bloodstream and targets proerythroblasts, signaling them to differentiate into mature RBCs.
Without EPO, RBC production does not proceed.
Clinical note: EPO can be produced in the lab and given to patients in certain contexts:
Kidney failure → insufficient endogenous EPO → treatment with EPO.
Chemotherapy → rapid destruction of rapidly dividing cells (including RBC precursors) → may require EPO to support RBC production.
RBC anatomy recap (context for later): RBCs contain no organelles; they are essentially a large hemoglobin-packed balloon cell.
Hematopoiesis vs erythropoiesis:
Hematopoiesis describes the general process of blood cell formation.
Erythropoiesis specifically refers to RBC production.
Platelet production (thrombopoiesis) details
Platelets come from the same initial stem cell (hemocytoblast) but follow a different differentiation path:
Hemocytoblast → megakaryoblast → megakaryocyte → platelets (fragments).
A hormone is required to drive this process: thrombopoietin (TPO).
TPO is produced by the liver.
TPO targets megakaryoblasts to promote their maturation into megakaryocytes.
Platelets are released as fragments from megakaryocytes (not true cells).
If the liver does not produce adequate TPO, platelet production can be impaired.
Platelet details:
Platelets are not cells (they are fragments). They act like cells in function but are cytoplasmic fragments.
Normal platelet count range:
150{,}000 ext{ to } 400{,}000 per microliter.Platelets play a key role in hemostasis (stopping bleeding) and clot formation.
Clinical aspects of platelets:
Thrombocytopenia (low platelets) → risk of excessive bleeding; symptoms include easy bruising, gum bleeding, etc. Clinical threshold mentioned: below
50{,}000 per microliter can be life-threatening due to bleeding risk.Thrombocytosis (high platelets) → risk of abnormal clotting; may be asymptomatic or cause clots.
Treatments referenced include platelet transfusions; discussion of thrombopoietin (TPO) limitations in clinical use.
Hemoglobin structure and RBC contents
RBCs contain hemoglobin, which is responsible for oxygen transport.
Hemoglobin (Hb) structure (adult Hb): made of 4 subunits: ext{alpha}1, ext{alpha}2, ext{beta}1, ext{beta}2}.
Each subunit contains a heme group with iron (Fe) at its center; iron is essential for oxygen binding.
Each Hb molecule can bind up to four oxygen molecules (one per heme group), though binding is variable depending on conditions.
Hb is a protein made of 4 subunits + 4 heme groups; iron in heme is crucial for oxygen binding.
The term fetal hemoglobin (HbF) exists but is not covered in detail here; the focus is on adult Hb (HbA).
A single RBC contains about 2.5 imes 10^8 Hb molecules (approximately 250,000,000) inside each cell.
Summary: RBCs are specialized for oxygen transport via hemoglobin; RBCs have no organelles; the hemoglobin content is the primary functional component.
Hemopoiesis scope and RBC production rate
Hematopoiesis vs erythropoiesis clarified:
Hematopoiesis = production of RBCs, WBCs, and platelets as a whole.
Erythropoiesis = specific production of RBCs.
RBC production rate:
Approximately 2.5 imes 10^6 RBCs are produced per second.
This rapid production helps maintain RBC numbers despite ongoing destruction.
RBC lifespan: RBCs live for several months due to lack of nucleus and limited repair capacity.
Destruction balance: As many RBCs are produced per second as are destroyed; this balance maintains stable RBC numbers and hematocrit.
Destruction of RBCs and bilirubin metabolism
Destruction of RBCs results in destruction of hemoglobin and the heme components.
For RBC destruction, a repeated calculation given: destruction occurs at a rate of 2.5 imes 10^6 RBCs per second, which correlates with hemoglobin breakdown.
Breakdown products: heme is catabolized, yielding iron, carbon monoxide, and bilirubin.
Iron is recovered and reused.
Carbon monoxide is produced as a byproduct of heme degradation (endogenous production).
Bilirubin is produced as a product of heme breakdown and is initially toxic (toxic bilirubin).
Liver processing of bilirubin:
1) RBCs are destroyed and hemoglobin is broken down, producing toxic bilirubin.
2) The toxic bilirubin is transported to the liver.
3) The liver metabolizes bilirubin to a non-toxic form (non-toxic bilirubin) via metabolic reactions.
4) Non-toxic bilirubin is delivered to the digestive tract and the kidneys for excretion.
5) In the digestive tract, bilirubin is excreted in feces; feces acquire their brown color partly due to bilirubin processing.
6) In urine, bilirubin is excreted in the urine; urine maintains a yellow color due to bilirubin clearance.Rationale for jaundice: Elevated bilirubin levels in the blood (hyperbilirubinemia) cause yellowing of skin and conjunctiva (jaundice).
Jaundice is a sign, not a disease, indicating elevated bilirubin; it can be prehepatic, hepatic, or posthepatic.
Jaundice types explained:
Prehepatic (before the liver): typically due to excessive destruction of RBCs (hemolysis). Examples include neonatal jaundice and hemolytic diseases (e.g., thalassemia, sickle cell anemia). Newborns often display jaundice because their hematocrit is high in utero (about 80 ext{%}) leading to higher RBC turnover; usually resolves on its own.
Hepatic (liver): due to liver dysfunction; insufficient bilirubin metabolism. Causes include cirrhosis (often due to alcoholism, drug toxicity like acetaminophen, viral hepatitis), liver cancer, or immature liver in premature infants.
Posthepatic/Obstructive (after the liver): bilirubin cannot be transported into the digestive tract due to obstruction (ductal blockages). Causes include gallstones, pancreatitis, tumors obstructing ducts. As a result, bilirubin backs up into the bloodstream, causing jaundice; bilirubin can be found in the blood and then excreted via kidneys.
Visual and clinical notes:
The color change in bilirubin processing explains why feces are brown and urine is yellow; bilirubin processing and excretion determine the color phenotypes.
Ductal blockages can lead to obstructive jaundice because bilirubin cannot reach the digestive tract, causing elevated blood bilirubin levels.
Additional discussion points from the lecture:
Kernicterus (severe bilirubin toxicity) is not covered in depth in this segment.
Hematocrit values are assumed known from prior lectures (normal ranges given elsewhere).
The liver’s role in bilirubin metabolism is critical to preventing toxicity and jaundice.
Anemia: definition, signs, and types
Definition: anemia = deficiency of hemoglobin, leading to reduced oxygen-carrying capacity of the blood.
Signs and symptoms of anemia (common across many etiologies):
Fatigue (due to decreased ATP production from less oxygen delivery).
Dyspnea (shortness of breath) on exertion.
Malaise (feeling unwell).
Pallor (pale skin) due to reduced red color from hemoglobin-bound oxygen.
Table of anemia causes (four major categories) with examples:
Loss of blood (bleeding): reduces RBCs and hemoglobin; example is menstrual blood loss (menses) and internal bleeding.
Nutrient deficiencies: iron deficiency is the most common cause; iron is required to make heme; without heme, RBCs cannot carry oxygen. Other nutritional causes include vitamin B12 and folate (B9) deficiencies.
Bone marrow damage (aplastic or immune-mediated): immune destruction of red bone marrow or toxic medications; leads to decreased production of RBCs (and often WBCs and platelets).
Genetic/congenital conditions: present from birth, such as thalassemia and sickle cell anemia.
Iron deficiency anemia (most common):
Diagnosis: low iron levels in blood tests.
Dietary sources: iron-rich foods, especially heme iron from meat; spinach and other vegetables contain non-heme iron but are less efficiently absorbed.
Treatment: increase iron intake; iron supplements, dietary changes, or iron shots; absorption can be enhanced with vitamin C, etc. Continue to emphasize that not all anemia is iron-deficiency; testing is needed.
Vitamin B12 deficiency (cobalamin):
B12 is necessary for the steps in RBC production; deficiency leads to fewer RBCs.
Primary dietary source: meat products; plant sources do not provide B12 unless fortified foods are used.
Vegan note: fortified foods help prevent B12 deficiency; B12 injections are another option.
Vitamin B9 (folate) deficiency:
B9 is essential for RBC production; deficiency reduces RBC production and hemoglobin synthesis.
Sources: folate-rich foods; fortified foods may be used; vegan sources exist in leafy greens and legumes.
Bone marrow damage / aplasia:
Diagnosis: bone marrow biopsy is required for definitive diagnosis; CBC alone cannot confirm.
Treatment: immunosuppressive therapy to dampen autoimmune destruction; bone marrow transplant can be curative but immune rejection risk remains.
Genetic anemias (two classic examples):
Thalassemia (alpha or beta): defective subunits in Hb; disease ranges from mild to severe; treatments include blood transfusions, bone marrow transplant, and potential gene therapy in the future.
Sickle cell anemia: mutation in beta subunit; causes Hb to polymerize and RBCs to sickle; RBCs can become occlusive in capillaries leading to ischemia; crisis is triggered by hypoxia, dehydration, or acidosis; treatments exist but not detailed here.
Concepts to know: sickle cell trait vs disease; crisis (vaso-occlusive) can cause tissue ischemia and severe pain; crises are episodic and can be life-threatening; various triggers and potential treatments exist.
Polycythemia (excess RBCs):
Definition: increased RBC concentration; hematocrit above normal range.
Potential advantages: improved oxygen-carrying capacity if mildly elevated; risks are associated with increased blood viscosity and heart workload.
Risks associated with high hematocrit: slower blood flow (stasis) and higher risk of blood clots.
Primary cause: secondary to hypoxia (low blood oxygen) which stimulates increased erythropoiesis as a compensatory mechanism.
Common scenarios that cause hypoxia: cardiovascular disease, pulmonary disease, smoking, living at high altitude (e.g., Denver, Mile High City).
Altitude adaptation: higher hematocrit at higher elevations to compensate for reduced ambient oxygen; up to about +5% hematocrit at moderate altitudes and more at very high elevations.
White blood cells (WBCs) and platelets (CBC context)
Complete blood count (CBC) purpose: provides hematocrit (RBC percentage), RBC count, hemoglobin concentration, WBC count, and platelet count.
Normal white blood cell (WBC) count:
Range: 5{,}000 ext{ to } 9{,}000 cells per microliter (total for all five WBC types).
WBC differential can be broken down by type (neutrophils, lymphocytes, monocytes, eosinophils, basophils).
Low WBC count (leukopenia): can occur with bone marrow damage or AIDS (HIV) due to immune system suppression.
High WBC count (leukocytosis): often indicates infection or inflammation; extremely high counts can occur with leukemia (very high counts, e.g., well above 100,000).
Platelets (thrombocytes):
Normal range: 150{,}000 ext{ to } 400{,}000 platelets per microliter.
Low platelets (thrombocytopenia): count < 150{,}000; potential symptoms include easy bruising, gum bleeding; risk increases as platelets drop below about 50{,}000.
High platelets (thrombocytosis): count > 400{,}000; often asymptomatic but can cause clumping and clot formation in some cases.
Causes of platelet abnormalities: immune destruction, bone marrow damage (aplastic processes), or disease states like lupus; thrombocytopenia can be associated with bone marrow aplasia; thrombocytosis can be driven by over-sensitivity to thrombopoietin (TPO).
Thrombopoietin (TPO) biology:
TPO is produced by the liver.
TPO targets megakaryocytes/megakaryoblasts to promote platelet production.
Some clinical conditions involve attempting to use TPO as a treatment for low platelets, but in practice, TPO therapy does not reliably correct thrombocytopenia in all cases.
Cancer and blood cell production:
Cancer can cause excessive production of certain blood cells; treatment may involve anticoagulants to prevent abnormal clotting, depending on the context.
Platelet function in hemostasis:
Platelets participate in two key hemostatic processes: platelet plug formation and coagulation (clot formation).
Platelets rapidly respond to vessel injury to seal small damages and limit bleeding.
Hemostasis: stopping bleeding
Hemostasis = stoppage of bleeding; two main processes involve platelets:
Platelet plug formation (primary hemostasis): platelets aggregate at the site of vascular injury to form a temporary plug.
Coagulation (secondary hemostasis): a cascade that stabilizes the platelet plug by forming a fibrin clot.
Vascular injury scenario (platelet plug formation narrative):
Step 1: Blood vessel is damaged or cut, causing inflammation at the site of injury.
Platelets adhere to exposed vessel connective tissue, become activated, release chemical mediators, and recruit more platelets to form a plug.
Note on the lecture flow: the teacher emphasizes that this is just the beginning of the platelet plug story; more details on clotting cascades (coagulation) and thrombus formation are covered in later lectures.
Quick recap of key links and processes
RBC production is driven by EPO from the kidneys; RBC maturation occurs through erythropoiesis; RBCs carry oxygen via hemoglobin.
Platelet production is driven by TPO from the liver; platelets arise from megakaryocytes and function in hemostasis.
Hemoglobin structure is critical for oxygen transport; iron in heme is essential for binding oxygen; adult Hb consists of 4 subunits with 4 heme groups; up to 4 O2 molecules can bind per Hb molecule; RBCs lack organelles and package large amounts of Hb (~2.5 imes 10^8 Hb molecules per RBC).
RBC destruction produces bilirubin; bilirubin is metabolized by the liver to a non-toxic form, excreted in feces and urine; elevated bilirubin causes jaundice, which can be prehepatic, hepatic, or posthepatic depending on underlying causes.
Anemia arises from various causes (blood loss, nutrient deficiencies, bone marrow damage, or congenital/genetic diseases); common etiologies include iron deficiency, B12 and folate deficiencies, aplastic anemia, thalassemia, and sickle cell disease.
Polycythemia reflects overly high RBC mass, often due to hypoxia; elevations in hematocrit increase viscosity and risk of thrombosis; altitude and cardiopulmonary diseases are common contributors.
CBC provides a snapshot of RBCs, WBCs, and platelets; typical normal ranges include WBCs: 5{,}000-9{,}000/µL and platelets: 150{,}000-400{,}000/µL; deviations can point to infection, immune disorders, marrow pathology, or hematologic diseases.
The clinical relevance of EPO and TPO: EPO treats anemia due to kidney failure or chemotherapy; TPO-based strategies exist but are not universally effective; both hormones illustrate how the body regulates blood cell production through organ-specific cytokines.
The lecture ends with a preview of the next topics: deeper dive into hemostasis, more on RBC destruction, and the broader implications for jaundice and blood disorders.